Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

In order to keep up with consumer needs, banks need to evolve pretty quickly and be ready to adapt to the future. But ...

Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.

Researchers have developed a new process that uses microwave flow reaction and recyclable solid catalysts to efficiently hydrolyze polysaccharides into simple sugars. The developed device utilizes a ...

Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...

Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...